Please assess the completion status of the following clinical trial:

Trial Title: Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 12 years and ≤ 50 years~* Glucose 6 phosphate dehydrogenase (G6PD) normal status defined by Carestart rapid diagnostic test or the G6PD qualitative test (OSMMR2000)~* Absence of symptomatic falciparum malaria, defined by fever on enrolment~* Presence of P. falciparum gametocytes on thick blood film at a density \>16 gametocytes/µL (i.e. ≥ gametocytes recorded in the thick film against 500 white blood cells)~* Absence of other non-P. falciparum species on blood film~* No allergies to study drugs~* No use of antimalarial drugs over the past 7 days (as reported by the participant)~* Hemoglobin ≥ 10 g/dL~* Individuals weighing \< = 80 kg~* No evidence of acute severe or chronic disease~* Written, informed consent~Exclusion Criteria:~* Age \< 12 years or \> 50 years~* Women who are pregnant or lactating~* Blood thick film negative for sexual stages of malaria~* Detection of a non-P. falciparum species by microscopy~* Previous reaction to study drugs / known allergy to study drugs~* Signs of severe malaria, including hyperparasitemia (defined as asexual parasitemia \> 100,000 parasites / µL)~* Signs of acute or chronic illness, including hepatitis~* The use of other medication (with the exception of paracetamol and/or aspirin)~* Consent not given~* G6PD-deficiency by Carestart rapid diagnostic test or the OSMMR2000 G6PD qualitative test~* Use of antimalarial drugs over the past 7 days (as reported by the participant)~* The use of other medication (with the exception of paracetamol and/or aspirin)~* Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically)~* Signs of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child Pugh stage B or C)~* Signs, symptoms or known renal impairment~* Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin \< 10 g/dL, platelets \< 50,000/μl, White Blood Cell count (WBC) \< 2000/μl, serum creatinine \>2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age.~* Family history of diseases leading to QT prolongation or recent treatment with drugs linked to QT prolongation~* Blood transfusion in the last 90 days.~* Consistent with the long half-life of tafenoquine, effective contraception should be continued for 5 half-lives (3 months) after the end of treatment.~* History of psychiatric disorders

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Dihydroartemisinin-Piperaquine (DP) (Type: ACTIVE_COMPARATOR): Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a low dose of 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg. Tafenoquine (TQ) on the first date of DP treatment.
- DP with 0.415mg/kg Tafenoquine (TQ) (Type: EXPERIMENTAL): Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.415mg/kg Tafenoquine (TQ) on the first date of DP treatment.
- DP with 0.83 mg/kg TQ (Type: EXPERIMENTAL): Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and a single dose of 0.83mg/kg Tafenoquine (TQ) on the first date of DP treatment.
- DP with 1.66mg/kg TQ (Type: EXPERIMENTAL): Subjects will receive Dihydroartemisinin-Piperaquine (DP) once daily for 3 days, and single dose of 1.66mg/kg Tafenoquine (TQ) on the first date of DP treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).